NASDAQ:XENE Xenon Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $33.31 +1.71 (+5.41%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$31.60▼$34.0650-Day Range$25.44▼$34.7052-Week Range$14.65▼$36.42Volume913,939 shsAverage Volume611,476 shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice Target$43.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Xenon Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.3% Upside$43.40 Price TargetShort InterestHealthy4.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.08) to ($3.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.51 out of 5 starsMedical Sector984th out of 1,433 stocksPharmaceutical Preparations Industry486th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.40, Xenon Pharmaceuticals has a forecasted upside of 30.3% from its current price of $33.31.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.54% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently decreased by 2.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 2.3 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xenon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for XENE on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.06% of the stock of Xenon Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.08) to ($3.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Xenon Pharmaceuticals (NASDAQ:XENE) StockXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.Read More XENE Stock News HeadlinesJune 29, 2022 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Lowered to "Sell" at StockNews.comJune 29, 2022 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) PT Lowered to $41.00June 27, 2022 | finance.yahoo.comXenon Pharmaceuticals' (NASDAQ:XENE) investors will be pleased with their enviable 884% return over the last five yearsJune 27, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesJune 23, 2022 | finance.yahoo.comXenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure FrequencyJune 23, 2022 | finance.yahoo.comWhy Xenon Pharma Flirted With A Breakout — And Then Sacrificed It AllJune 23, 2022 | seekingalpha.comHot Stocks: OXY rises as Buffett adds shares, SNOW pops on upgrade, KBH also gains and XENE declinesJune 23, 2022 | seekingalpha.comXenon Pharmaceuticals slides on pricing $250M equity offeringJune 22, 2022 | finance.yahoo.comXenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 ProgramJune 21, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDAJune 16, 2022 | americanbankingnews.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)June 14, 2022 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $44.00 Average PT from AnalystsJune 1, 2022 | finance.yahoo.comXenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare ConferenceMay 30, 2022 | finance.yahoo.comWe're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash WiselyMay 10, 2022 | investing.comXenon Pharmaceuticals Tops Q1 EPS by 6cMay 10, 2022 | seekingalpha.comXenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | finance.yahoo.comXenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 9, 2022 | finance.yahoo.comSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2022 | nasdaq.comNotable Two Hundred Day Moving Average Cross - XENEMay 3, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate UpdateMay 3, 2022 | finance.yahoo.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate UpdateMay 3, 2022 | nz.finance.yahoo.comXenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)April 29, 2022 | finance.yahoo.comXenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 100% Above Its Share PriceApril 4, 2022 | finance.yahoo.comXenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare ConferenceMarch 22, 2022 | finance.yahoo.comXenon Pharmaceuticals to Present at Stifel 2022 CNS DaysSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees149Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/07/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$43.40 High Stock Price Forecast$48.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+30.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,880,000.00 Net Margins-360.80% Pretax Margin-363.84% Return on Equity-20.94% Return on Assets-19.75% Debt Debt-to-Equity RatioN/A Current Ratio68.36 Quick Ratio68.36 Sales & Book Value Annual Sales$18.44 million Price / Sales95.94 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book3.17Miscellaneous Outstanding Shares53,110,000Free Float49,888,000Market Cap$1.77 billion OptionableOptionable Beta1.58 Xenon Pharmaceuticals Frequently Asked Questions Should I buy or sell Xenon Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xenon Pharmaceuticals stock. View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks. What is Xenon Pharmaceuticals' stock price forecast for 2022? 6 equities research analysts have issued 12 month price targets for Xenon Pharmaceuticals' stock. Their XENE stock forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $43.40 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Xenon Pharmaceuticals' stock performed in 2022? Xenon Pharmaceuticals' stock was trading at $31.24 at the start of the year. Since then, XENE stock has increased by 6.6% and is now trading at $33.31. View the best growth stocks for 2022 here. When is Xenon Pharmaceuticals' next earnings date? Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Xenon Pharmaceuticals. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. The biopharmaceutical company had revenue of $8.77 million for the quarter, compared to analysts' expectations of $9.22 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.94% and a negative net margin of 360.80%. During the same period in the prior year, the company earned ($0.42) earnings per share. View Xenon Pharmaceuticals' earnings history. Who are Xenon Pharmaceuticals' key executives? Xenon Pharmaceuticals' management team includes the following people: Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director (Age 46, Pay $957.16k)Ms. Sherry Aulin, Chief Financial Officer (Age 38, Pay $458.64k)Dr. Christopher John Kenney M.D., Chief Medical Officer (Age 51, Pay $494.83k) (LinkedIn Profile)Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor RelationsMs. Shelley McCloskey B.A., Sr. VP of HR (Age 62)Dr. Robin P. Sherrington Ph.D., Exec. VP of Strategy & Innovation (Age 61)Dr. James R. Empfield Ph.D., Exec. VP of Drug Discovery (Age 61)Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D OperationsDr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer (Age 43)Dr. Kenneth Sommerville, Interim Chief Medical Officer Who are some of Xenon Pharmaceuticals' key competitors? Some companies that are related to Xenon Pharmaceuticals include Sarepta Therapeutics (SRPT), Perrigo (PRGO), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Karuna Therapeutics (KRTX), Cytokinetics (CYTK) and Mirati Therapeutics (MRTX). View all of XENE's competitors. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI). What is Xenon Pharmaceuticals' stock symbol? Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE." How do I buy shares of Xenon Pharmaceuticals? Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xenon Pharmaceuticals' stock price today? One share of XENE stock can currently be purchased for approximately $33.31. How much money does Xenon Pharmaceuticals make? Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $1.77 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. How many employees does Xenon Pharmaceuticals have? Xenon Pharmaceuticals employs 149 workers across the globe. How can I contact Xenon Pharmaceuticals? Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450. This page (NASDAQ:XENE) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
